Status:
UNKNOWN
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Lead Sponsor:
Assiut University
Conditions:
Hepatitis C
Eligibility:
All Genders
Brief Summary
Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype...
Detailed Description
Treatment of hepatitis C virus, a virus infecting over one hundred seventy million worldwide, has evolved over the last two decades and moved from interferon-alpha monotherapy to pegylated interferon-...
Eligibility Criteria
Inclusion
- Patients with chronic hepatitis C only will be included.
- Patients who are eligible for treatment by DAAs only.
Exclusion
- Cirrhotic patients will be excluded based on USS, APRI score index and FIB4 index.
- Hepatitis B infected patients will also be excluded.
- Patients with current or previous history of neuropsychiatric disorders will be excluded.
- Failure to obtain consent.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03268317
Start Date
January 1 2018
End Date
January 1 2020
Last Update
August 31 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.